Frankfurt
30.01.26 | 08:21
0,040 Euro
0,00 % 0,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,052 | 0,058 | 08:46 | |
| 0,052 | 0,058 | 08:43 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Hemostemix Inc (2): Hemostemix appoints Hsiang as business consultant | 3 | Stockwatch | ||
| Di | Hemostemix Inc.: Hemostemix Appoints Renowned Vascular Surgeon and Principal Investigator, Dr. York Hsiang, as Business Consultant to Advance First Nations-Led Healthcare Partnerships | 137 | Newsfile | Calgary, Alberta--(Newsfile Corp. - February 3, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous stem cell company treating those who suffer in pain from peripheral... ► Artikel lesen | |
| 16.01. | Hemostemix Inc.: Hemostemix Receives FDA Support for Its Basket Protocol Approach | 411 | Newsfile | Calgary, Alberta--(Newsfile Corp. - January 16, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous stem cell company treating those who suffer in pain from peripheral... ► Artikel lesen | |
| 01.01. | Hemostemix Inc (2): Hemostemix closes $480,000 financing | 4 | Stockwatch | ||
| 31.12.25 | Hemostemix Inc.: Hemostemix Closes $480,000 Private Placement at $0.12 per Share | 294 | Newsfile | Calgary, Alberta--(Newsfile Corp. - December 31, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (the "Company" or "Hemostemix"), an autologous stem cell company treating those who... ► Artikel lesen | |
| HEMOSTEMIX Aktie jetzt für 0€ handeln | |||||
| 23.12.25 | Hemostemix Inc (2): Hemostemix appoints Alper to scientific advisory board | 3 | Stockwatch | ||
| 23.12.25 | Hemostemix Inc.: Hemostemix Appoints Dr. David B. Alper, to Lead Multidisciplinary Physician Education in the Use of ACP-01 | 376 | Newsfile | Calgary, Alberta--(Newsfile Corp. - December 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), an autologous stem cell company treating those who... ► Artikel lesen | |
| 19.12.25 | Hemostemix Inc (2): Hemostemix 4,713,090-unit private placement | 4 | Stockwatch | ||
| 12.12.25 | Hemostemix Inc (2): Hemostemix grants options to buy 963,000 shares | 2 | Stockwatch | ||
| 11.12.25 | Hemostemix Inc.: Hemostemix CEO Introduces Conformal Consciousness Hypothesis A = E/(hv) | 295 | Newsfile | Calgary, Alberta--(Newsfile Corp. - December 11, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) the leading autologous (patient's own) stem cell therapy company offering VesCell (ACP-01)... ► Artikel lesen | |
| 11.12.25 | Hemostemix Inc.: Hemostemix Grants Stock Options | 165 | Newsfile | Calgary, Alberta--(Newsfile Corp. - December 11, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that in accordance with its stock... ► Artikel lesen | |
| 11.12.25 | Hemostemix Inc (2): Hemostemix basket protocol pre-IND meeting set for Jan. | 3 | Stockwatch | ||
| 10.12.25 | Hemostemix Inc. Announces FDA Pre-IND Meeting and NBPP of $960,000 | 362 | Newsfile | Calgary, Alberta--(Newsfile Corp. - December 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own) stem cell therapy... ► Artikel lesen | |
| 05.12.25 | Hemostemix Inc (2): Hemostemix appoints Harding as patient care director | 3 | Stockwatch | ||
| 04.12.25 | Hemostemix Inc.: Hemostemix Welcomes Shaune Harding, OStJ, RN as Director of Patient Care & Clinical Operations | 324 | Newsfile | Calgary, Alberta--(Newsfile Corp. - December 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), a leader in autologous stem cell therapeutics for ischemic... ► Artikel lesen | |
| 03.12.25 | Hemostemix Inc.: Hemostemix Featured at Innovations in Wound Healing 2025, Key West, December 11-14 | 423 | Newsfile | Calgary, Alberta--(Newsfile Corp. - December 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce its participation as a premier... ► Artikel lesen | |
| 02.12.25 | Hemostemix Inc.: Hemostemix to Attend DFCon San Antonio and Closed its Private Placement | 342 | Newsfile | Calgary, Alberta--(Newsfile Corp. - December 2, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is proud to announce its participation in DFCon 2025, hosted by the American Limb Preservation... ► Artikel lesen | |
| 27.11.25 | Hemostemix Inc (2): Hemostemix to acquire two cardiology practices | 15 | Stockwatch | ||
| 26.11.25 | Hemostemix Inc.: Hemostemix Starts its Roll-up of Cardiology Practices, Acquiring its First Two | 424 | Newsfile | Calgary, Alberta--(Newsfile Corp. - November 26, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), is pleased to announce a binding Letter of Intent for the acquisition of the first two... ► Artikel lesen | |
| 21.11.25 | Hemostemix Inc (2): Hemostemix's ACP-01 dementia trial to be led by Shankle | 1 | Stockwatch |
1 2 3 4 5 Weiter >>
90 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,100 | 0,00 % | Zink-Boom, Turnaround, Biotech-Wachstum: So profitieren Sie mit Pasinex Resources, Puma und Evotec | In volatilen Märkten suchen Anleger nach außergewöhnlichen Chancen. Drei Unternehmen stechen dabei heraus. Ein Rohstoffunternehmen mit außergewöhnlichen Zink-Projekten, ein Sportartikelhersteller im... ► Artikel lesen | |
| QIAGEN | 43,475 | 0,00 % | Qiagen übertrifft Markterwartungen im vierten Quartal | DJ Qiagen übertrifft Markterwartungen im vierten Quartal
DOW JONES--Qiagen hat im Schlussquartal 2025 den Umsatz gesteigert, der operative Gewinn ging gegenüber dem Vorjahr zurück. 2026 rechnet... ► Artikel lesen | |
| PAION | 0,110 | -24,14 % | XFRA MISTRADE ANTRAG IN ISIN DE000A3E5EG5 WIRD GEPRUEFT | Fuer folgende Geschaefte in der ISIN DE000A3E5EG5, Wertpapier-Name: PAION AG INH O.N., wird ein Mistrade-Antrag geprueft:ISIN Datum Zeit Volumen Preis Fair Value (AS)DE000A3E5EG5 02.02.2026 08:13:40 300 0... ► Artikel lesen | |
| VALNEVA | 4,030 | -1,32 % | Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ | Lyon (France), Sao Paulo, (Brazil), February 3, 2026 -Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company and Instituto Butantan, one of the world's largest biomedical research... ► Artikel lesen | |
| EPIGENOMICS | 0,870 | 0,00 % | PTA-Adhoc: Epigenomics AG: Vorläufiges Jahresergebnis zum 31. Dezember 2025 | DJ PTA-Adhoc: Epigenomics AG: Vorläufiges Jahresergebnis zum 31. Dezember 2025
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR
Epigenomics AG: Vorläufiges Jahresergebnis zum... ► Artikel lesen | |
| NOVAVAX | 6,735 | +0,75 % | NOVAVAX INC: Schwäche mit Signalwirkung | ||
| STRYKER | 305,60 | -0,68 % | Stryker Corporation: Stryker declares an $0.88 per share quarterly dividend | Portage, Michigan, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable April 30, 2026, to shareholders... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 39,000 | 0,00 % | Morningstar, Inc.: Morningstar Completes Acquisition of CRSP and Extends Relationship with Vanguard | The CRSP integration unites two trusted sources of market insight, reinforcing a shared commitment to transparency, quality, and investor-focused solutions and solidifying Morningstar's position... ► Artikel lesen | |
| CORE ONE LABS | - | - | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| CO.DON | 0,017 | -21,43 % | EQS-PVR: CO.DON AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: CO.DON AG
CO.DON AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
07.01.2026 / 12:38 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| OCUGEN | 1,121 | -0,71 % | Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious adverse events reported across the Phase 1 and Phase 2 clinical... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,82 | +0,14 % | Avidity Biosciences, Inc. - 8-K, Current Report | ||
| STRUCTURE THERAPEUTICS | 73,21 | 0,00 % | Structure Therapeutics gains on report suggesting it may be a top takeover target | ||
| RECURSION PHARMACEUTICALS | 3,565 | 0,00 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 305,95 | 0,00 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
HEMOSTEMIX INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,040 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HEMOSTEMIX INC finden Sie auf Wallstreet Online.